379 related articles for article (PubMed ID: 30913985)
21. The Relationship between Protein-Protein Interactions and Liquid-Liquid Phase Separation for Monoclonal Antibodies.
Sibanda N; Shanmugam RK; Curtis R
Mol Pharm; 2023 May; 20(5):2662-2674. PubMed ID: 37039349
[TBL] [Abstract][Full Text] [Related]
22. Liquid-liquid phase separation of tau protein: The crucial role of electrostatic interactions.
Boyko S; Qi X; Chen TH; Surewicz K; Surewicz WK
J Biol Chem; 2019 Jul; 294(29):11054-11059. PubMed ID: 31097543
[TBL] [Abstract][Full Text] [Related]
23. Investigation of anomalous charge variant profile reveals discrete pH-dependent conformations and conformation-dependent charge states within the CDR3 loop of a therapeutic mAb.
Lan W; Valente JJ; Ilott A; Chennamsetty N; Liu Z; Rizzo JM; Yamniuk AP; Qiu D; Shackman HM; Bolgar MS
MAbs; 2020; 12(1):1763138. PubMed ID: 32432964
[TBL] [Abstract][Full Text] [Related]
24. Solubility Challenges in High Concentration Monoclonal Antibody Formulations: Relationship with Amino Acid Sequence and Intermolecular Interactions.
Pindrus M; Shire SJ; Kelley RF; Demeule B; Wong R; Xu Y; Yadav S
Mol Pharm; 2015 Nov; 12(11):3896-907. PubMed ID: 26407030
[TBL] [Abstract][Full Text] [Related]
25. Characterization of Excipient Effects on Reversible Self-Association, Backbone Flexibility, and Solution Properties of an IgG1 Monoclonal Antibody at High Concentrations: Part 1.
Hu Y; Arora J; Joshi SB; Esfandiary R; Middaugh CR; Weis DD; Volkin DB
J Pharm Sci; 2020 Jan; 109(1):340-352. PubMed ID: 31201906
[TBL] [Abstract][Full Text] [Related]
26. Liquid-Liquid Phase Separation of Tau Driven by Hydrophobic Interaction Facilitates Fibrillization of Tau.
Lin Y; Fichou Y; Longhini AP; Llanes LC; Yin P; Bazan GC; Kosik KS; Han S
J Mol Biol; 2021 Jan; 433(2):166731. PubMed ID: 33279579
[TBL] [Abstract][Full Text] [Related]
27. Charge block-driven liquid-liquid phase separation - mechanism and biological roles.
Koyama T; Iso N; Norizoe Y; Sakaue T; Yoshimura SH
J Cell Sci; 2024 Jun; 137(11):. PubMed ID: 38855848
[TBL] [Abstract][Full Text] [Related]
28. Reduction of therapeutic antibody self-association using yeast-display selections and machine learning.
Makowski EK; Chen H; Lambert M; Bennett EM; Eschmann NS; Zhang Y; Zupancic JM; Desai AA; Smith MD; Lou W; Fernando A; Tully T; Gallo CJ; Lin L; Tessier PM
MAbs; 2022; 14(1):2146629. PubMed ID: 36433737
[TBL] [Abstract][Full Text] [Related]
29. Condensation of the N-terminal domain of human topoisomerase 1 is driven by electrostatic interactions and tuned by its charge distribution.
Bianchi G; Mangiagalli M; Ami D; Ahmed J; Lombardi S; Longhi S; Natalello A; Tompa P; Brocca S
Int J Biol Macromol; 2024 Jan; 254(Pt 1):127754. PubMed ID: 38287572
[TBL] [Abstract][Full Text] [Related]
30. Mitigation of liquid-liquid phase separation of a monoclonal antibody by mutations of negative charges on the Fab surface.
Matsuoka T; Miyauchi R; Nagaoka N; Hasegawa J
PLoS One; 2020; 15(10):e0240673. PubMed ID: 33125371
[TBL] [Abstract][Full Text] [Related]
31. Opalescence of an IgG2 monoclonal antibody solution as it relates to liquid-liquid phase separation.
Mason BD; Zhang L; Remmele RL; Zhang J
J Pharm Sci; 2011 Nov; 100(11):4587-96. PubMed ID: 21638285
[TBL] [Abstract][Full Text] [Related]
32. Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo.
Dobson CL; Devine PW; Phillips JJ; Higazi DR; Lloyd C; Popovic B; Arnold J; Buchanan A; Lewis A; Goodman J; van der Walle CF; Thornton P; Vinall L; Lowne D; Aagaard A; Olsson LL; Ridderstad Wollberg A; Welsh F; Karamanos TK; Pashley CL; Iadanza MG; Ranson NA; Ashcroft AE; Kippen AD; Vaughan TJ; Radford SE; Lowe DC
Sci Rep; 2016 Dec; 6():38644. PubMed ID: 27995962
[TBL] [Abstract][Full Text] [Related]
33. Improved Solution-State Properties of Monoclonal Antibodies by Targeted Mutations.
Kuhn AB; Kube S; Karow-Zwick AR; Seeliger D; Garidel P; Blech M; Schäfer LV
J Phys Chem B; 2017 Dec; 121(48):10818-10827. PubMed ID: 29135256
[TBL] [Abstract][Full Text] [Related]
34. Antibody engineering to improve manufacturability.
Wijesuriya SD; Pongo E; Tomic M; Zhang F; Garcia-Rodriquez C; Conrad F; Farr-Jones S; Marks JD; Horwitz AH
Protein Expr Purif; 2018 Sep; 149():75-83. PubMed ID: 29655788
[TBL] [Abstract][Full Text] [Related]
35. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.
Giles I; Lambrianides N; Latchman D; Chen P; Chukwuocha R; Isenberg D; Rahman A
Arthritis Res Ther; 2005; 7(1):R47-56. PubMed ID: 15642142
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of protein engineering and process optimization approaches to enhance antibody drug manufacturability.
Conley GP; Viswanathan M; Hou Y; Rank DL; Lindberg AP; Cramer SM; Ladner RC; Nixon AE; Chen J
Biotechnol Bioeng; 2011 Nov; 108(11):2634-44. PubMed ID: 21618474
[TBL] [Abstract][Full Text] [Related]
37. First-order nucleation and subsequent growth promote liquid-liquid phase separation of a model IgG1 mAb.
Tian Z; Xu L; Zhang N; Qian F
Int J Pharm; 2020 Oct; 588():119681. PubMed ID: 32721563
[TBL] [Abstract][Full Text] [Related]
38. Effect of Excipients on Liquid-Liquid Phase Separation and Aggregation in Dual Variable Domain Immunoglobulin Protein Solutions.
Raut AS; Kalonia DS
Mol Pharm; 2016 Mar; 13(3):774-83. PubMed ID: 26756795
[TBL] [Abstract][Full Text] [Related]
39. Structure-based engineering of a monoclonal antibody for improved solubility.
Wu SJ; Luo J; O'Neil KT; Kang J; Lacy ER; Canziani G; Baker A; Huang M; Tang QM; Raju TS; Jacobs SA; Teplyakov A; Gilliland GL; Feng Y
Protein Eng Des Sel; 2010 Aug; 23(8):643-51. PubMed ID: 20543007
[TBL] [Abstract][Full Text] [Related]
40. Suppression of Electrostatic Mediated Antibody Liquid-Liquid Phase Separation by Charged and Noncharged Preferentially Excluded Excipients.
Banks DD; Cordia JF
Mol Pharm; 2021 Mar; 18(3):1285-1292. PubMed ID: 33555888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
